These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20556670)

  • 21. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
    N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
    Hochberg MC; Greenspan S; Wasnich RD; Miller P; Thompson DE; Ross PD
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1586-92. PubMed ID: 11932287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO).
    Adami S; Maugeri D; Toscano V; Topa G; Carminiti M; Brancati A; Massarotti M; Osella G; Malavolta N; Iolascon G; Cagnoni C; Camozzi V; Corradini C; Nardi A; Migliaccio S; Ulivieri FM; Resmini G; Valle D; Tauchmanovà L; Silvestri S;
    Clin Exp Rheumatol; 2011; 29(3):477-84. PubMed ID: 21640043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.
    Watts NB; Lewiecki EM; Miller PD; Baim S
    J Clin Densitom; 2008; 11(4):473-7. PubMed ID: 18562228
    [No Abstract]   [Full Text] [Related]  

  • 26. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB; Geusens P; Barton IP; Felsenberg D
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures.
    Johansson H; Odén A; McCloskey EV; Kanis JA
    Osteoporos Int; 2014 Jan; 25(1):235-41. PubMed ID: 23974856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fracture risk following an osteoporotic fracture.
    Johnell O; Kanis JA; Odén A; Sernbo I; Redlund-Johnell I; Petterson C; De Laet C; Jönsson B
    Osteoporos Int; 2004 Mar; 15(3):175-9. PubMed ID: 14691617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
    Austin M; Yang YC; Vittinghoff E; Adami S; Boonen S; Bauer DC; Bianchi G; Bolognese MA; Christiansen C; Eastell R; Grauer A; Hawkins F; Kendler DL; Oliveri B; McClung MR; Reid IR; Siris ES; Zanchetta J; Zerbini CA; Libanati C; Cummings SR;
    J Bone Miner Res; 2012 Mar; 27(3):687-93. PubMed ID: 22095631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
    Hochberg MC
    Curr Osteoporos Rep; 2008 Sep; 6(3):89-94. PubMed ID: 18752769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing osteoporotic fractures in older people.
    McCloskey E
    Practitioner; 2011 Jan; 255(1736):19-22, 2-3. PubMed ID: 21370710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.
    Chan DC; Chang CH; Lim LC; Brnabic AJM; Tsauo JY; Burge R; Hsiao FY; Jin L; Gürbüz S; Yang RS
    Osteoporos Int; 2016 Sep; 27(9):2855-2865. PubMed ID: 27172935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minor, major, low-trauma, and high-trauma fractures: what are the subsequent fracture risks and how do they vary?
    Warriner AH; Patkar NM; Yun H; Delzell E
    Curr Osteoporos Rep; 2011 Sep; 9(3):122-8. PubMed ID: 21698358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fracture risk and antiresorptive medication use in older women in the USA.
    Gehlbach SH; Avrunin JS; Puleo E; Spaeth R
    Osteoporos Int; 2007 Jun; 18(6):805-10. PubMed ID: 17206400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of individual fracture risk: FRAX and beyond.
    van den Bergh JP; van Geel TA; Lems WF; Geusens PP
    Curr Osteoporos Rep; 2010 Sep; 8(3):131-7. PubMed ID: 20563901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.